Synergy CHC (OTCQB:SNYR) appointed Jeffrey Kadanoff as its CFO, effective Nov, 1, 2017.
Mr. Kadanoff’s appointment strengthens Synergy’s ability to raise financing, and supports the company’s growth organically through corporate initiatives and by further acquisition, the company said in a statement.
Mr. Kadanoff was formerly CFO of Knight Therapeutics (TSX:GUD). Prior to joining Knight, he was a principal with Bain, where he served as a strategy consultant for 14 years.
Jack Ross, chairman and CEO, of Synergy said he has worked closely in partnership with Jeffrey over the last two and half years, and seen firsthand how he can add value to Synergy.
Mr. Kadanoff said he has witnessed Synergy’s impressive growth beginning with the acquisition of FOCUSfactor and continuing with the development of The Synergy Effect, and “I look forward to sustaining that trend.”
Knight was involved in providing financing for Synergy’s major acquisitions and Mr. Kadanoff led the business relationship with Synergy on behalf of Knight.
